We are currently using novel techniques to measure amyloid-beta metabolism in humans. We hypothesize that there is a decrease in amyloid-beta clearance in people who develop Alzheimer's Disease compared to people who do not.
Our goals are to quantify the pathophysiologic changes in humans that lead to Alzheimer disease, and develop new biomarkers for antecedent detection of AD and to test pharmacodynamic effects of proposed disease modifying therapies.
Research Publications
Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM (2006 Jun 25). Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med. Full Article >
Yan P, Hu X, Song H, Yin K, Bateman RJ, Cirrito JR, Xiao Q, Hsu FF, Turk JW, Xu J, Hsu CY, Holtzman DM, Lee JM (2006 Jun 20). Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. J Biol Chem. Full Article >
Contact Info
Randall Bateman, M.D.
Office Location: Biotechnology Bldg 107
Office Phone: 314-286-1967
Lab Phone: 314-747-7066
Campus Box: 8111
Fax: 314-362-2244
batemanr@wustl.edu
